JCP

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Koda, M
Right arrow Articles by Sulkowski, S
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Koda, M
Right arrow Articles by Sulkowski, S
Journal of Clinical Pathology 2005;58:645-649
© 2005 BMJ Publishing Group Ltd & Association of Clinical Pathologists


ORIGINAL ARTICLE

Expression of insulin receptor substrate 1 in primary breast cancer and lymph node metastases

M Koda, M Sulkowska, L Kanczuga-Koda, S Sulkowski

Department of Clinical Pathology, Medical University of Bialystok, Waszyngtona 13, 15-269 Bialystok, Poland

Correspondence to:
Professor S Sulkowski
Department of Clinical Pathology, Medical University of Bialystok, Waszyngtona 13, 15-269 Bialystok, Poland; sulek{at}zeus.amb.edu.pl Background: Insulin receptor substrate 1 (IRS-1) transmits signals from the insulin-like growth factor I receptor (IGF-IR) and insulin receptor (IR) and has been associated with the pathogenesis of cancer. IRS-1 downregulation has been suggested to play a role in breast cancer progression, but no simultaneous assessments of IRS-1 expression in primary breast cancer and metastases have been performed.

Aims: To assess IRS-1 expression in primary and metastatic breast cancer.

Methods: IRS-1 expression was analysed by means of immunohistochemistry in 109 samples of primary breast cancer and in 42 matched primary and metastatic tumours. In addition, IRS-1 expression was correlated with selected clinicopathological features, including oestrogen receptor {alpha} (ER{alpha}) and proliferation marker Ki-67 status.

Results: Positive cytoplasmic IRS-1 immunostaining was found in 69.7% (76 of 109) and 76.2% (32 of 42) of the primary and metastatic tumours, respectively. Both IRS-1 positive and IRS-1 negative primary tumours produced IRS-1 positive and IRS-1 negative metastases. IRS-1 expression in primary tumours correlated with poorly differentiated (G3) breast cancer (p<0.005) and with lymph node involvement (p<0.05). In the subgroup of ER{alpha} positive primary tumours, IRS-1 expression positively correlated with Ki-67 (p<0.02, r = 0.351), but in the subgroup of ER{alpha} negative primary tumours there was a negative correlation (p<0.03, r = –0.509). IRS-1 expression in lymph node metastases correlated with neither ER{alpha} nor Ki-67.

Conclusions: IRS-1 might be involved in breast cancer progression. Knowledge about differences between primary and metastatic tumours might help to understand mechanisms of breast cancer progression and lead to the development of more effective anticancer drugs.


Abbreviations: E2, 17ß-oestradiol; ER{alpha}, oestrogen receptor {alpha}; IGF-I, insulin-like growth factor I; IGF-IR, insulin-like growth factor I receptor; IR, insulin receptor; IRS-1, insulin receptor substrate 1

Keywords: breast cancer; lymph node metastases; insulin receptor substrate-1; oestrogen receptor {alpha}; proliferation




This article has been cited by other articles:


Home page
EndocrinologyHome page
N. M. Ramocki, H. R. Wilkins, S. T. Magness, J. G. Simmons, B. P. Scull, G. H. Lee, K. K. McNaughton, and P. K. Lund
Insulin Receptor Substrate-1 Deficiency Promotes Apoptosis in the Putative Intestinal Crypt Stem Cell Region, Limits Apcmin/+ Tumors, and Regulates Sox9
Endocrinology, January 1, 2008; 149(1): 261 - 267.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. Ravikumar, G. Perez-Liz, L. Del Vale, D. R. Soprano, and K. J. Soprano
Insulin Receptor Substrate-1 Is an Important Mediator of Ovarian Cancer Cell Growth Suppression by All-trans Retinoic Acid
Cancer Res., October 1, 2007; 67(19): 9266 - 9275.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Pathol.Home page
D. Sisci, C. Morelli, C. Garofalo, F. Romeo, L. Morabito, F. Casaburi, E. Middea, S. Cascio, E. Brunelli, S. Ando, et al.
Expression of nuclear insulin receptor substrate 1 in breast cancer
J. Clin. Pathol., June 1, 2007; 60(6): 633 - 641.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
T.-J. Liu, T. LaFortune, T. Honda, O. Ohmori, S. Hatakeyama, T. Meyer, D. Jackson, J. de Groot, and W.K. A. Yung
Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo
Mol. Cancer Ther., April 1, 2007; 6(4): 1357 - 1367.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
R. K. Dearth, X. Cui, H.-J. Kim, I. Kuiatse, N. A. Lawrence, X. Zhang, J. Divisova, O. L. Britton, S. Mohsin, D. C. Allred, et al.
Mammary Tumorigenesis and Metastasis Caused by Overexpression of Insulin Receptor Substrate 1 (IRS-1) or IRS-2
Mol. Cell. Biol., December 15, 2006; 26(24): 9302 - 9314.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
Z. Ma, S. L. Gibson, M. A. Byrne, J. Zhang, M. F. White, and L. M. Shaw
Suppression of Insulin Receptor Substrate 1 (IRS-1) Promotes Mammary Tumor Metastasis
Mol. Cell. Biol., December 15, 2006; 26(24): 9338 - 9351.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Journal of Clinical Pathology Molecular Pathology
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2005 by the BMJ Publishing Group Ltd & Association of Clinical Pathologists.